AAO 2020: Alimera highlights NEW DAY Study for sustained-release intravitreal implant

Conference|AAO

Rick Eiswirth, president and CEO of Alimera Sciences, provides an update on the company’s clinical trial that aims to evaluate its fluocinolone acetonide intravitreal implant 0.19 mg (Iluvien) as a baseline therapy for diabetic macular edema.


Rick Eiswirth, president and CEO of Alimera Sciences, provides an update on the company’s clinical trial that aims to evaluate its fluocinolone acetonide intravitreal implant 0.19 mg (Iluvien) as a baseline therapy for diabetic macular edema.

Related Videos
Related Content

ARVO 2023: Kiora Pharmaceuticals presented preliminary results for KIO-301

May 1st 2023

Integrating AI to manage DR in a primary care setting

December 1st 2020

ARVO 2023: Lineage Cell Therapeutics presents results of RG6501 Phase 1/2a clinical trial for treatment of GA progression

April 29th 2023

What to expect from virtual AAO 2020

November 5th 2020

ARVO 2023: Preclinical data for Ashvattha Therapeutics anti-VEGF nanomedicine D-4517.2 shared at annual meeting

April 28th 2023

ARVO 2023: Phase 2 ongoing study of LBS-008 data shared for treatment of adolescent Stargardt disease

April 27th 2023

ARVO 2023: Kiora Pharmaceuticals presented preliminary results for KIO-301

May 1st 2023

Integrating AI to manage DR in a primary care setting

December 1st 2020

ARVO 2023: Lineage Cell Therapeutics presents results of RG6501 Phase 1/2a clinical trial for treatment of GA progression

April 29th 2023

What to expect from virtual AAO 2020

November 5th 2020

ARVO 2023: Preclinical data for Ashvattha Therapeutics anti-VEGF nanomedicine D-4517.2 shared at annual meeting

April 28th 2023

ARVO 2023: Phase 2 ongoing study of LBS-008 data shared for treatment of adolescent Stargardt disease

April 27th 2023

ARVO 2023: Kiora Pharmaceuticals presented preliminary results for KIO-301

May 1st 2023

Integrating AI to manage DR in a primary care setting

December 1st 2020

ARVO 2023: Lineage Cell Therapeutics presents results of RG6501 Phase 1/2a clinical trial for treatment of GA progression

April 29th 2023

What to expect from virtual AAO 2020

November 5th 2020

ARVO 2023: Preclinical data for Ashvattha Therapeutics anti-VEGF nanomedicine D-4517.2 shared at annual meeting

April 28th 2023

ARVO 2023: Phase 2 ongoing study of LBS-008 data shared for treatment of adolescent Stargardt disease

April 27th 2023
© 2023 MJH Life Sciences

All rights reserved.